Successful Closure of a Recurrent Full-Thickness Macular Hole with Medical Therapy: A Case Report
Medical therapy for macular hole
DOI:
https://doi.org/10.62856/djcro.v8.58Keywords:
full-thickness macular hole, macular edema, pars plana vitrectomy, medical therapy, non-surgical therapyAbstract
A 73-year-old male with a past medical history of pseudophakia and posterior vitreous detachment (PVD) in both eyes, epiretinal membrane (ERM) in his right eye (OD), lattice degeneration OD, and prior, localized retinal detachment OD status post laser retinopexy presented with progressive vision loss OD. The patient was found to have a full thickness macular hole (FTMH) which was successfully closed with pars plana vitrectomy (PPV), the standard of treatment for a primary FTMH. Six years postoperatively, the macular hole reopened. The recurrent FTMH was managed with intravitreal injection of triamcinolone acetonide (Kenalog) 2.0 mg/0.05 mL and topical dorzolamide-timolol 2%/0.5%, ketorolac 0.4%, and prednisolone acetate 1% drops. This conservative management resulted in complete resolution of the recurrent FTMH. This case illustrates the efficacy of topical therapy in managing recurrent FTMH, highlighting a non-surgical alternative in select patients.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
The Contributor assigns to Duke, during the full term of copyright and any extensions or renewals, all copyright in and to the Manuscript, and all rights therein, including but not limited to the right to publish, republish, transmit, sell, distribute and otherwise use the Manuscript in whole or in part in electronic editions of the DJCRO and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so. "Manuscript" means the article submitted by the Contributor for publication in the DJCRO (including any embedded rich media) and all subsequent versions. The definition of Manuscript does not extend to any supporting information submitted with or referred to in the Manuscript ("Supporting Information"). To the extent that any Supporting Information is submitted to the DJCRO, Duke is granted a perpetual, non-exclusive license to publish, republish, transmit, sell, distribute and otherwise use this Supporting Information in whole or in part in electronic and print editions of the DJCRO and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so. If the Manuscript was shared as a preprint, the Contributor grants to Duke exclusivity as to any rights retained by the Contributor in the preprint.
Reproduction, posting, transmission or other distribution or use of the final Manuscript in whole or in part in any medium by the Contributor as permitted by this Agreement requires a citation to the DJCRO suitable in form and content as follows: (Contributor(s), Title of Manuscript, Journal Title, Journal Volume, Copyright© [year], Digital Object Identifier [DOI] link to final Manuscript). Links to the final article on the DJCRO website are also encouraged where appropriate.
